BUZZ-Neurogene drops after pausing part of gene therapy study due to serious side effect

Reuters11-18

** Drug developer Neurogene's shares fall 19% to $28 premarket

** Company says it has paused testing high-dosage version of its experimental gene therapy after reporting a serious treatment related side-effect in one of the participants

** Neurogene says the participant is in critical condition due to hyperinflammatory syndrome, a rare and life-threatening immune response

** The gene therapy, NGN-401, is being developed to treat Rett syndrome, a rare genetic neurological disorder that occurs most often in girls and affects their ability to speak, walk, eat, and even breathe easily

** Company says the U.S. Food and Drug Administration has allowed the early-mid-stage study to continue testing patients with the low-dosage version

** As of last close, stock up 78% YTD

(Reporting by Mariam Sunny in Bengaluru) ((Mariam.ESunny@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment